Kamada (Kamada) Additional Paid-In Capital : $265.8 Mil(As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Kamada Additional Paid-In Capital?

Kamada's quarterly additional paid-in capital increased from Jun. 2023 ($210.7 Mil) to Sep. 2023 ($265.7 Mil) and increased from Sep. 2023 ($265.7 Mil) to Dec. 2023 ($265.8 Mil).

Kamada's annual additional paid-in capital increased from Dec. 2021 ($210.2 Mil) to Dec. 2022 ($210.5 Mil) and increased from Dec. 2022 ($210.5 Mil) to Dec. 2023 ($265.8 Mil).

Kamada Additional Paid-In Capital Historical Data

The historical data trend for Kamada's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Additional Paid-In Capital Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

180.82

209.76

210.20

210.50

265.85

Kamada Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															210.50	210.67	210.73	265.70	265.85

Kamada Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Kamada Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kamada's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (Kamada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

KMDA:Israel

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.